Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:4043
Structure:
Synonyms:
11 beta-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione
11-beta-Hydroxy-6-alpha-methylpregn-4-ene-3,20-dione
11-hydroxy-6-methylpregn-4-ene-3,20-dione
11-hydroxy-6-methylprogesterone
11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione
11beta-Hydroxy-6alpha-methylprogesterone
17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodec
2668-66-8
6-alpha-Methyl-11-beta-hydroxyprogesterone
6alpha-Methyl-11beta-hydroxyprogesterone
AC-13158
AC1L1HAB
AC1Q5CD6
AR-1C0479
C22H32O3
CID4043
EINECS 220-208-7
GSH 1043
HMS
HMS Liquifilm
Hydroxymesterone
LS-118712
Medriabioptal
Medrifar
Medrisona
Medrisona [INN-Spanish]
Medrisone
Medrisone [DCIT]
Medritonic
Medriusar
Medrocort
Medroftal
MEDRYSONE
Medrysone [USAN:INN]
Medrysonum
Medrysonum [INN-Latin]
NSC 63278
NSC-63278
Pregn-4-ene-3,20-dione, 11-beta-hydroxy-6-alpha-methyl-
Pregn-4-ene-3,20-dione, 11-hydroxy-6-methyl-, (6alpha,11beta)-
Pregn-4-ene-3,20-dione, 11beta-hydroxy-6alpha-methyl-
Pregn-4-ene-3,20-dione, 11beta-hydroxy-6alpha-methyl- (8CI)
Progesterone, 11beta-hydroxy-6alpha-methyl-
Sedesterol
Spectramedryn
U 8471
U-8471
UNII-D2UFC189XF
Visudrisone
Side-Effects:
Side-EffectFrequency
glaucoma0
keratitis0
cataract0
blurred vision0
viral infection0
uveitis0
ocular infection0
corneal ulcer0
ptosis0
ulcer0
allergic reaction0

Target

show target details
Uniprot ID:CP2C9_HUMAN
Synonyms:
(R)-limonene 6-monooxygenase
(S)-limonene 6-monooxygenase
(S)-limonene 7-monooxygenase
CYPIIC9
Cytochrome P450 2C9
P-450MP
P450 MP-4/MP-8
P450 PB-1
S-mephenytoin 4-hydroxylase
EC-Numbers:1.14.13.48
1.14.13.49
1.14.13.80
Organism:Homo sapiens
Human
PDB IDs:1OG2 1OG5 1R9O
Structure:
1R9O

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

16476124
Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba.. K H Liu; M J Kim; B H Jeon; J H Shon; I J Cha; K H Cho; S S Lee; J G Shin (2006) Journal of clinical pharmacy and therapeutics display abstract
OBJECTIVE: We evaluated the potential of 15 herbal medicines (HMs), commonly used in Korea, to inhibit the catalytic activities of several cytochrome P450 (CYP) isoforms and microsomal NADPH-CYP reductase. METHODS: The abilities of 1-1000 microg/mL of freeze-dried aqueous extracts of 15 HMs to inhibit phenacetin O-deethylation (CYP1A2), tolbutamide 4-methylhydroxylation (CYP2C9), S-mephenytoin 4'-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), midazolam 1-hydroxylation (CYP3A4) and NADPH-CYP reductase were tested using human liver microsomes. RESULTS: The HMs Epimedii herba, Glycyrrhizae radix and Leonuri herba inhibited one or more of the CYP isoforms or NADPH-CYP reductase. Of the three HMs, Epimedii herba extracts were the most potent inhibitors of several CYP isoforms (IC(50) 67.5 microg/mL for CYP2C19, 104.8 microg/mL for CYP2E1, 110.9 microg/mL for CYP2C9, 121.9 microg/mL for CYP3A4, 157.8 microg/mL for CYP2D6 and 168.7 microg/mL for CYP1A2) and NADPH-CYP reductase (IC(50) 185.9 microg/mL ). CONCLUSION: These results suggest that some of the HMs used in Korea have the potential to inhibit CYP isoforms in vitro. Although the plasma concentrations of the active constituents of the HMs were not determined, some herbs could cause clinically significant interactions because the usual doses of those individual herbs are several grams of freeze-dried extracts. Controlled trials to test the significance of these results are necessary.